Prognostic Scoring System for radiofrequency ablation: Usefulness of Albumin-bilirubin (ALBI)-grade

淳, 平岡; 卓, 熊田; 詠, 糸林; 邦彦, 辻; 達, 石川; 昌史, 広岡; 和也, 狩山; 一裕, 能祖; 俊史, 多田; 秀徳, 豊田; 陽一, 日浅; 浩二郎, 道堯

doi:10.2957/kanzo.57.312

Cited by 8 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study comparing the efficacy between first-line ATE+BEV and lenvatinib, lenvatinib showed non-inferior PFS compared to ATE+BEV. 19 In a Japanese single-arm study showing oncologic outcomes of lenvatinib after ATE+BEV failure, 20 the median OS and PFS were comparable to those of Yoo et al 13 (OS, 15.7 months in Japanese study vs. 16.6 months in Yoo et al 13 ; PFS, 4.4 vs. 6.1 months). Another Japanese study reported that the median OS and PFS of patients treated with lenvatinib after ATE+BEV failure were 13.5 months and 4.0 months, respectively, similar to previous findings.…”

Section: Discussionmentioning

confidence: 68%

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Chon,

Kim,

Kim

et al. 2024

Clin Mol Hepatol

View full text Add to dashboard Cite

Study Highlights• This study compared treatment and survival outcomes of lenvatinib and sorafenib as second-line treatments for advanced HCC following ATE+BEV failure.• Although overall survival was comparable between the two treatments after adjustment, lenvatinib treatment demonstrated significantly better PFS than sorafenib, both before and after adjusting for patient characteristics.• The findings enhance our understanding of effective treatment strategies for advanced HCC, suggesting the potential role of lenvatinib for improving PFS.• These insights are valuable for optimizing therapy in advanced HCC patients who do not respond to first line ATE+BEV treatment, thereby helping to bridge the gap between the current clinical guidelines and the real-world treatment for advanced HCC.

show abstract

Section: Discussionmentioning

confidence: 68%

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Chon,

Kim,

Kim

et al. 2024

Clin Mol Hepatol

View full text Add to dashboard Cite

show abstract

“…Hepatic reserve function was assessed using Child-Pugh classification (15) and albumin-bilirubin (ALBI) score (16,17) and modified ALBI grade (mALBI): ALBI grade 2 divided into two subgrades (2a and 2b) with an ALBI score of -2.27 as the cut-off value (9).…”

Section: Assessments Of Hepatic Reserve Functionmentioning

confidence: 99%

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Ohama,

Hiraoka,

Tada

et al. 2023

Preprint

View full text Add to dashboard Cite

Background/Aim: The present study aimed to develop detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving Atezolizumab plus Bevacizumab (Atez/Bev). Methods: Between September 2020 and January 2023, the patients treated with Atez/Bev were enrolled (n=719, males 577, median age 74 years). Factors involved in overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression-free survival (PFS) were examined retrospectively, and the prognostic ability of the newly system was compared to CRAFITY score using concordance index (c-index) and Akaike Information Criterion (AIC) results. Results: Cox-hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used for IMnunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI-De) scoring. For IMABALI-De scores of 0/1/2/3/4/5, OS was not applicable (NA)/NA/26.11/18.79/14.07/8.32 months (P<0.001; AIC 2788.67, c-index 0.699), while for CRAFITY scores of 0/1/2, OS was 26.11/20.29/11.32 months (p<0.001; AIC 2864.54, c-index 0.606). PFS for those IMABALI-De scores was 21.75/12.89/9.18/8.0/5.0/3.75 months (P<0.001; AIC 5203.32, c-index 0.623) and for the CRAFITY scores was10.32/7.68/3.57 months (p<0.001; AIC 5246.61, c-index 0.574). IMABALI-De score had better AIC and c-index results as compared to CRAFITY score for both OS and PFS. Conclusion: The proposed IMABALI-De score may have a favorable prognostic predictive ability for uHCC patients with Atez/Bev.

show abstract

“…Recently, the ALBI grading system has been shown to stratify HCC patients across BCLC stages (54). Several studies have reported the superiority of ALBI grade over Child-Pugh classification to assess liver function for therapeutic decision making (55). Further investigation will be required to clarify a better assessment system of liver function for the selection of optimal treatment for HCC with BCLC stage B.…”

Section: ) Evaluation Of Liver Functionmentioning

confidence: 99%

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects

Torimura

Iwamoto

2021

Clin Mol Hepatol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is usually accompanied by chronic liver damage, which sometimes influences the selection of HCC treatment. The Barcelona Clinic Liver Cancer (BCLC) staging system, which was first introduced in 1999, is the most commonly used worldwide. Although the intermediate-stage (BCLC stage B) includes the largest number and heterogeneous HCC patients, the recommended treatment option is transarterial chemoembolization (TACE) only. However, recent progress in radical treatments such as hepatic resection, liver transplantation, radiation therapy, and percutaneous therapy has made it possible to treat selected patients with BCLC stage B HCC. Radical treatments are expected to prolong survival time. To-date, TACE has also progressed. In addition to conventional TACE, balloon-occluded TACE and drug-eluting beads TACE are available. These new modalities of TACE will improve therapeutic efficacy and reduce adverse events. One of the most serious concerns of TACE is that repeated TACE reduces the treatment effect and induces liver function impairment. The decision on when TACE should be interrupted is complex. Many molecular targeted agents are now available, and immune checkpoint inhibitors will soon be available for HCC patients with Child-Pugh class A worldwide. Under these circumstances, in patients with TACE unsuitability, switching to molecular targeted agents before deterioration of liver function might improve the prognosis compared to repeated TACE. We should pay attention to stop TACE in TACE-unsuitable HCC patients as it can induce the deterioration of liver function.

show abstract

Prognostic Scoring System for radiofrequency ablation: Usefulness of Albumin-bilirubin (ALBI)-grade

Cited by 8 publications

References 14 publications

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects

Contact Info

Product

Resources

About